@article{38a0838605ed4a08b13fdbd7b9726955,
title = "Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.",
author = "Evanthia Galanis and Anderson, \{S. Keith\} and Miller, \{C. Ryan\} and Sarkaria, \{Jann N.\} and Kurt Jaeckle and Buckner, \{Jan C.\} and Ligon, \{Keith L.\} and Ballman, \{Karla V.\} and Moore, \{Dennis F.\} and Michael Nebozhyn and Andrey Loboda and David Schiff and Ahluwalia, \{Manmeet Singh\} and Lee, \{Eudocia Q.\} and Gerstner, \{Elizabeth R.\} and Lesser, \{Glenn J.\} and Michael Prados and Grossman, \{Stuart A.\} and Jane Cerhan and Caterina Giannini and Wen, \{Patrick Y.\}",
note = "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly diagnosed glioblastoma. Patients received oral vorinostat (300 or 400 mg/day) on days 1-5 weekly during temozolomide chemoradiation.",
year = "2018",
month = mar,
day = "27",
doi = "10.1093/NEUONC/NOX161",
language = "American English",
volume = "20",
journal = "Neuro-oncology",
}